1. The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon
   Yasar Ahmed et al, 2021, Oncology CrossRef
2. Single-sEV profiling identifies the TACSTD2 + sEV subpopulation as a factor of tumor susceptibility in the elderly
   Nannan Ning et al, 2024, Journal of Nanobiotechnology CrossRef
3. Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments
   Joshua E. Reuss et al, 2021, Clinical Lung Cancer CrossRef
4. siRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells
   XIAO-YAN GAO et al, 2015, Experimental and Therapeutic Medicine CrossRef
5. Novel Formulations and New Mechanisms of Delivering Chemotherapy
   Thomas E. Stinchcombe, 2014, American Society of Clinical Oncology Educational Book CrossRef
6. The Role of TROP2 in BCC and Cutaneous SCC: A Clinical and Immunohistochemical Study
   Azza Gaber Antar Farag et al, 2021, Clinical, Cosmetic and Investigational Dermatology CrossRef
7. Antibody-drug conjugates in lung cancer: dawn of a new era?
   Niamh Coleman et al, 2023, npj Precision Oncology CrossRef
8. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
   Thomas M. Cardillo et al, 2015, Bioconjugate Chemistry CrossRef
9. Antibody–drug conjugates for lung cancer in the era of personalized oncology
   Biagio Ricciuti et al, 2021, Seminars in Cancer Biology CrossRef
10. Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
    Rebecca Suk Heist et al, 2017, Journal of Clinical Oncology CrossRef
11. Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy
    Ticiana Leal et al, 2023, Expert Review of Anticancer Therapy CrossRef
12. Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors
    Shutan Liao et al, 2021, Drug Development Research CrossRef
13. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)
    Claudia Parisi et al, 2023, Cancer Treatment Reviews CrossRef
14. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
    David M. Goldenberg et al, 2018, Oncotarget CrossRef
15. Clinical impact of TROP2 in non‐small lung cancers and its correlation with abnormal p53 nuclear accumulation
    Remi Mito et al, 2020, Pathology International CrossRef
16. Flot-2 Expression Correlates with EGFR Levels and Poor Prognosis in Surgically Resected Non-Small Cell Lung Cancer
    Qiuyuan Wen et al, 2015, PLOS ONE CrossRef
17. Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer
    Lorenzo Belluomini et al, 2023, Expert Opinion on Biological Therapy CrossRef
18. Trop2: Jack of All Trades, Master of None
    Sára Lenárt et al, 2020, Cancers CrossRef
19. Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer
    Xinlin Liu et al, 2022, Pharmacology & Therapeutics CrossRef
20. Incorporation of CD40 ligand enhances the immunogenicity of tumor‑associated calcium signal transducer 2 virus‑like particles against lung cancer
    Wang Xi et al, 2018, International Journal of Molecular Medicine CrossRef
21. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC
    Benjamin P Levy et al, 2023, Future Oncology CrossRef
22. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies
    Melissa Johnson et al, 2022, Lung Cancer CrossRef
23. Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model
    Yitian Wu et al, 2024, EJNMMI Radiopharmacy and Chemistry CrossRef
24. Trophoblast cell surface antigen 2 expression predicts outcome in oral squamous cell carcinomas
    Mauricio Rocha Dourado et al, 2022, Oral Diseases CrossRef
25. Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments
    Shota Omori et al, 2022, Journal of Cancer Research and Clinical Oncology CrossRef